Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Breast Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Breast Neoplasm

Cancer Family

Breast Neoplasm

CI-CAN-00000007Explore in graph →

Non-malignant2,894 active trials43 approved drugs310 evidence items

NCIt: C2910
OncoTree: BNNOS
MeSH: D000069584
MeSH: D001943

Overview
Statistics
Survival
Genomics33
Variants & evidence310
Drugs79
Trials13867
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (268)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 226–250 of 268 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
· Mol Cancer Ther · 2012 · PMID 22294718 · validated civic_curation pubmed
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
· Oncogene · 2010 · PMID 20473330 · validated civic_curation pubmed
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
· Oncogene · 2011 · PMID 21358673 · validated civic_curation pubmed
Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.
· Nat Commun · 2016 · PMID 27694828 · validated civic_curation pubmed
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
· Cancer Discov · 2017 · PMID 28274957 · validated civic_curation pubmed
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
· Cancer Res · 2020 · PMID 32973082 · validated civic_curation pubmed
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
· Mol Cancer Ther · 2015 · PMID 25398829

Showing 226–250 of 268 publications

← Previous
1
…
9
10
11
Next →

· validated civic_curation

Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.

· Tumour Biol · 2016 · PMID 26596839 · validated civic_curation pubmed

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

· Int J Cancer · 2016 · PMID 26686064 · validated civic_curation pubmed

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

· Oncotarget · 2015 · PMID 25883215 · validated civic_curation pubmed

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

· Oncotarget · 2014 · PMID 25153719 · validated civic_curation pubmed

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

· Tumour Biol · 2013 · PMID 23881388 · validated civic_curation pubmed

SF3B1 mutations constitute a novel therapeutic target in breast cancer.

· J Pathol · 2015 · PMID 25424858 · validated civic_curation pubmed

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

· Cancer Res · 2008 · PMID 18829560 · validated civic_curation pubmed

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

· Breast Cancer Res · 2009 · PMID 19874578 · validated civic_curation pubmed

High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.

· Clin Cancer Res · 2022 · PMID 34593528 · validated civic_curation pubmed

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.

· PLoS One · 2016 · PMID 26751376 · validated civic_curation pubmed

Targeting Akt3 signaling in triple-negative breast cancer.

· Cancer Res · 2014 · PMID 24335962 · validated civic_curation pubmed

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.

· Clin Cancer Res · 2000 · PMID 11051239 · validated civic_curation pubmed

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

· Mol Cancer Res · 2009 · PMID 19737969 · validated civic_curation pubmed

Martelotto et al. J Pathol 2015

· 2015 · PMID 26095796 · validated cbioportal_study pubmed

Tan et al. Nat Genet 2015

· 2015 · PMID 26437033 · validated cbioportal_study pubmed

Garcia-Recio et al. Nat Cancer 2023

· 2023 · PMID 36585450 · validated cbioportal_study pubmed

Shah et al. Nature

· PMID 22495314 · validated cbioportal_study pubmed

Eirew et al. Nature 2015

· 2015 · PMID 25470049 · validated cbioportal_study pubmed